clinical trial · NCT03927105
Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma
University of Michigan Rogel Cancer Center·phase2·completed·n = 4
Peripheral T Cell LymphomaNivolumabcabiralizumab
brief summary
A multicenter trial evaluating the combination of nivolumab and the antagonistic CSF-1R monoclonal antibody cabiralizumab (BMS-986227) in patients with relapsed/refractory peripheral T cell lymphoma
started
Apr 25, 2019
primary completion
Nov 1, 2019
completion
Jul 6, 2023
last updated
May 7, 2026
detailed description
Enrollment to this study was discontinued after four subjects due to industry-related changes to the Cabiralizumab program.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol